drugset
drugset / Trial / NCT01791192

Study of FTY720 in Patients With Uveitis

NCT01791192 ↗

Phase 2 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

Timeline

Start
2013-11
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule — —

Indications

uveitis